The multicenter, open label, dose-ranging study will evaluate the effectiveness of SPI-2012 in comparison to a fixed and standard dose of Amgen Inc.’s (AMGN) Neulasta (pegfilgrastim) as a concurrent ...
Spectrum Pharmaceuticals Initiates Phase 2 Study of Long-Acting GCSF Drug Candidate, SPI-2012, for t
HENDERSON, Nev.--(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in ...
As 2012 nears its end, the rear-view mirror is full of ups and downs in the health care sector. One company that had plenty of both is small-cap Spectrum Pharmaceuticals. Here are the major milestones ...
The Spectrum Pharmaceuticals growth party is over. The bladder cancer drug aqaziquone blew up Thursday after two late-stage clinical trials failed. Spectrum was counting on seeking U.S. approval for ...
HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology ...
Spectrum Pharmaceuticals (NASDAQ: SPPI - News) and Allos Therapeutics, Inc. (NASDAQ: ALTH - News) today announced that they have signed a definitive agreement under which Spectrum will acquire all of ...
The Fool looks back at 2012 for up-and-down Spectrum Pharmaceuticals. All about Allos What was the biggest development for Spectrum in 2012? The acquisition of Allos Therapeutics ranks at the top of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results